SCHEMBL13039697

SCHEMBL13039697

CCOC(=O)c1cc(/C=C/c2ccccc2)no1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 5/20 0.49
ALDH1A1 P00352 5/20 0.47
HPGD P15428 5/20 0.47
KDM4E B2RXH2 4/20 0.47
POLB P06746 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GLA P06280 1/20 0.46
PPARG P37231 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
MAPT P10636 1/20 0.45
XBP1 P17861 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
GRM4 Q14833 1/20 0.45
RAB9A P51151 3/20 0.41
LMNA P02545 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13039700 0.80 CYP1A2 (0.46) ADORA3ALDH1A1HPGDKDM4EPOLB
SCHEMBL13039689 0.76 ADORA3 (0.43) ADORA3ALDH1A1HPGDKDM4EPOLB
SCHEMBL892695 0.75 SMN1; SMN2 (0.58) ALDH1A1HPGDKDM4EPOLBCYP1A2
SCHEMBL2672809 0.74 ALDH1A1 (0.35) ALDH1A1POLBCYP2C19MEN1KMT2A
SCHEMBL19224631 0.74 KLKB1 (0.49) ALDH1A1POLBL3MBTL1RAB9ALMNA
SCHEMBL15322929 0.74 HPGDS (0.56) ADORA3ALDH1A1HPGDKDM4EPOLB
SCHEMBL15322927 0.74 HPGDS (0.56) ADORA3ALDH1A1HPGDKDM4EPOLB
SCHEMBL17967253 0.73 MAPT (0.47) ALDH1A1HPGDKDM4EPOLBHSD17B10
SCHEMBL20278723 0.73 L3MBTL1 (0.50) ALDH1A1CYP1A2KMT2AL3MBTL1MAPT
SCHEMBL7421798 0.73 ALDH1A1 (0.52) ADORA3ALDH1A1HPGDKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100279963-A1 DICARBONYL DERIVATIVES AND METHODS OF USE ABRAXIS BIOSCIENCE, LLC (US) 2010-11-04 US disclosed
US-20100279963-A1 DICARBONYL DERIVATIVES AND METHODS OF USE ABRAXIS BIOSCIENCE, LLC (US) 2010-11-04 US disclosed
US-7799954-B2 Dicarbonyl derivatives and methods of use ABRAXIS BIOSCIENCE, LLC (US) 2010-09-21 US disclosed
US-7799954-B2 Dicarbonyl derivatives and methods of use ABRAXIS BIOSCIENCE, LLC (US) 2010-09-21 US disclosed
US-20080146586-A1 DICARBONYL DERIVATIVES AND METHODS OF USE ABRAXIS BIOSCIENCE (US) 2008-06-19 US disclosed
US-20080146586-A1 DICARBONYL DERIVATIVES AND METHODS OF USE ABRAXIS BIOSCIENCE (US) 2008-06-19 US disclosed
WO-2008064060-A2 DICARBONYL DERIVATIVES AND METHODS OF USE ABRAXIS BIOSCIENCE, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146586-A1 DICARBONYL DERIVATIVES AND METHODS OF USE AADAC, DCK, MLYCD ADORA3 4041/4885ALDH1A1 1688/4885HPGD 1608/4885
US-20100279963-A1 DICARBONYL DERIVATIVES AND METHODS OF USE AADAC, DCK, MLYCD ADORA3 4041/4885ALDH1A1 1688/4885HPGD 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.